ONMD · OneMedNet Corporation

This delisting notice signals a material risk to OneMedNet’s exchange listing status and investor liquidity. The $1.00 bid price deficiency reflects sustained market skepticism about the Company’s financial viability, operational scale, or growth prospects — though the filing does not disclose underlying causes such as revenue trends, cash position, or governance issues. Nasdaq’s 180-day grace period is standard but time-bound: failure to meet the ten-day $1.00 threshold by October 12, 2026 triggers automatic delisting unless the Company qualifies for and is granted a second compliance period. Qualification hinges on satisfying other listing standards — notably market value of publicly held shares — which are not addressed in the filing, creating uncertainty about eligibility. While the Company states it 'may consider' a reverse stock split, no board action, timeline, or shareholder approval process is disclosed, and such actions carry dilution and market perception risks. Delisting would likely restrict institutional ownership, reduce analyst coverage, impair access to capital, and trigger contractual defaults in some agreements — all without requiring further SEC disclosure beyond this 8-K. Investors should monitor bid price performance closely through October 12 and watch for follow-up disclosures regarding remedial actions or Nasdaq’s determination on second-period eligibility.